Status:
RECRUITING
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Brain Metastases
Radionecrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis...
Detailed Description
Brain metastases are frequent secondary sites in the evolution of cancers, with an incidence of all cancers combined of about 20% and up to 40% in the later phases of the disease. Among these metastas...
Eligibility Criteria
Inclusion
- Patients \> 18 years of age
- Histologically proven primary lung cancer
- Histologically proven or not brain metastases
- Irradiated metastases
- Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy
- Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI
- Patients affiliated to a social security scheme
Exclusion
- Opposition to the study
- Contraindication to MRI
- Refusal of imaging by the patient
- Patient with state medical aid (unless exemption from affiliation)
- Severe cognitive impairment making informed consent impossible
- Patients under guardianship or deprived of liberty
Key Trial Info
Start Date :
February 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 15 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05977803
Start Date
February 15 2024
End Date
February 15 2027
Last Update
April 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bichat-Claude Bernard
Paris, France, 75018